An Open-label, Multicenter, Phase 2 Study Evaluating the Efficacy and Safety of Daratumumab in Pediatric and Young Adult Subjects 1 and 30 Years of Age with Relapsed/Refractory Precursor B-cell or T-cell Acute Lympholastic Leukemia or Lymphoblastic Lymphoma

This Study is
No Longer Enrolling

Details
Age

Child to Adult

Type of Study

Treatment

Locations

Childrens Hospital Colorado

Study ID

Protocol Number: 18-0867

More information available at ClinicalTrials.gov: NCT03384654

Categories

Not finding the right Study for you? Join ResearchMatch, a nation-wide registry connecting volunteers and researchers